|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.88 / 6.60|
Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.
Top Line Results Expected in 3Q 2017
Phase 2 MDD clinical trial results expected in 3Q17, Extended runway of cash into 3Q18
Investigating New Patient Cohort with Cervical Injury
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.